Clopidogrel efficacy of antiplatelet

Based on the results of research conducted by dr. Pamela Moceri MD and colleagues from the Cardiology Department, Pasteur University Hospital of Nice, Nice, France, can be concluded that the decrease in effectiveness of clopidogrel because of clopidogrel in conjunction with the PPI can be overcome by increasing the dose of clopidogrel to 2-fold, or replace the PPI with ranitidine.

Apparently from the results of this study increased attention to interactions that may occur and decrease the effectiveness of antiplatelet agent clopidogrel. In 2009, the FDA (Food and Drug Administration) warnings regarding the concurrent administration of clopidogrel with omeprazole. In his warning, the FDA also stated that patients with high risk of heart attacks and strokes are treated with clopidogrel will not gain the full benefit of clopidogrel when administered together with omeprazole. FDA at that time recommend changes to the label clopidogrel with a new celebration, the interaction of clopidogrel with omeprazole and other drugs that inhibit the enzyme CYP2C19. Patients who were treated using clopidogrel and require medications that reduce stomach acid is recommended to be treated using H2 antagonists such as ranitidine or famotidine, because the FDA has confidence that these drugs do not interact with clopidogrel. While drugs are not recommended in conjunction with clopidogrel dosing among others such as cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine, and ticlopidine.

Clopidogrel has been used extensively to overcome aterotrombotik events, both in patients with cardiovascular events, cerebrovascular, and peripheral arterial disease, as well as in patients with high cardiovascular risk. In studies such as CAPRIE, CURE, CLARITY-TIMI well as other research, the

Clopidogrel therapy Hulu (Upstream) Post-STEMI

The results of a large-scale observational study conducted recently strengthened guidelines updated in Europe and America to recommend the administration of clopidogrel as early as possible post-STEMI (ST-segment elevation myocardial infarction). This finding revealed by dr. David Erlinge and colleagues from Sweden, published in European Heart Journal in early July 2011. These researchers found that clopidogrel therapy upstream (upstream) before patients undergo catheterization associated with a decreased risk of death or myocardial infarction (myocardial infarction, MI) in patients with STEMI who underwent PCI (percutaneous coronary intervention) primer. Clopidogrel, which slow its effects, usually given shortly after the occurrence of STEMI (before primary PCI), although to date there is no definitive evidence regarding this practice.